Fujifilm Biotechnologies

Fujifilm Rebrands Life Sciences Companies

Fujifilm Irvine Scientific becomes Fujifilm Biosciences, and Fujifilm Diosynth Biotechnologies will be known as Fujifilm Biotechnologies.

Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.

The CDMO/CMO Report

Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?

Fujifilm Invests Additional $1.2 Billion in CDMO Business in North Carolina

Fujifilm announced an additional investment of $1.2 billion in its large-scale cell culture contract development and manufacturing organization (CDMO) business to further expand the planned Fujifilm Diosynth Biotechnologies facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion. Plans for the new site were unveiled in September last year.

Fujifilm Diosynth Announces New US Cell Culture Production Facility

Fujifilm Diosynth Biotechnologies unveiled its new $2 billion large-scale cell culture manufacturing facility in Holly Springs, North Carolina, US.

Fujifilm Invests $1.6 Billion for Cell Culture Expansion

Fujifilm is preparing to invest $1.6 billion to ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.

Ramping Up Biomanufacturing Capacity

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.

Fujifilm Selects US Cell Site, Inks Biotech Deals

Fujifilm Diosynth Biotechnologies has chosen Holly Springs in North Carolina as the site of its new large-cell culture production site in the US. The company first announced its plans in January, saying it planned to spend more than $2 billion on the project, which will be the largest end-to-end cell culture biopharma CDMO facility in North America when it starts up by spring 2025.

Fujifilm Diosynth Biotechnologies, Piramal Announce Strategic Alliance

Fujifilm Diosynth Biotechnologies Expands Mammalian Cell Culture cGMP Capabilities